id stringlengths 36 64 | Type stringclasses 2
values | Section_id stringclasses 4
values | Primary_id stringclasses 811
values | Secondary_id stringclasses 330
values | Statement stringlengths 31 411 | Label stringclasses 2
values | Intervention stringclasses 1
value | Causal_type null | Secondary_evidence_index null | Primary_Document dict | Primary_Section listlengths 2 146 | Secondary_Document dict | Secondary_Section listlengths 3 76 ⌀ | source_id stringlengths 36 36 | augmentation dict |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
5bc844fc-e852-4270-bfaf-36ea9eface3d | Comparison | Intervention | NCT01928186 | NCT00684983 | All the primary trial participants do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, in conrast all the secondary trial subjects receive these. | Contradiction | Base_Statement | null | null | {
"Adverse Events": [
"Adverse Events 1:",
" Total: 0/28 (0.00%)"
],
"Eligibility": [
"Inclusion Criteria:",
" A new diagnosis of invasive breast cancer > 1.0 cm in size, ER+ clinical stage I-III",
" Patient must have surgical resection followed by systemic adjuvant therapy with an aromatas... | [
"INTERVENTION 1: ",
" Diagnostic (FLT PET)",
" Patients with early stage, ER positive primary breast cancer undergo FLT PET scan at baseline and 1-6 weeks after the start of standard endocrine treatment. The surgery follows 1-7 days after the second FLT PET scan.",
" Tracer used in the FLT PET (positron em... | {
"Adverse Events": [
"Adverse Events 1:",
" Total: 4/19 (21.05%)",
" Hemoglobin decreased 0/19 (0.00%)",
" Hemolysis 0/19 (0.00%)",
" Diarrhea 2/19 (10.53%)",
" Ear, nose and throat examination abnormal 0/19 (0.00%)",
" Esophageal ulcer 0/19 (0.00%)",
" Gastritis 1/19 (5.26%)",... | [
"INTERVENTION 1: ",
" Arm A",
" Patients receive oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. lapatinib ditosylate: Given PO and capecitabine: Given PO",
"INTERVE... | 5bc844fc-e852-4270-bfaf-36ea9eface3d | {
"candidate": null,
"checks": null,
"effect": "original",
"fields": null,
"intent": null,
"mode": "original",
"strategies": null,
"summary": null,
"task_label_status": null,
"variant": 0
} |
5bc844fc-e852-4270-bfaf-36ea9eface3d__aug_substitute-syntactic_2 | Comparison | Intervention | NCT01928186 | NCT00684983 | While all the secondary trial subjects' receive cixutumumab IV, oral lapatinib ditosylate, and oral capecitabine, none of the primary trial participants receive them. | Contradiction | Base_Statement | null | null | {
"Adverse Events": [
"Adverse Events 1:",
" Total: 0/28 (0.00%)"
],
"Eligibility": [
"Inclusion Criteria:",
" A new diagnosis of invasive breast cancer > 1.0 cm in size, ER+ clinical stage I-III",
" Patient must have surgical resection followed by systemic adjuvant therapy with an aromatas... | [
"INTERVENTION 1: ",
" Diagnostic (FLT PET)",
" Patients with early stage, ER positive primary breast cancer undergo FLT PET scan at baseline and 1-6 weeks after the start of standard endocrine treatment. The surgery follows 1-7 days after the second FLT PET scan.",
" Tracer used in the FLT PET (positron em... | {
"Adverse Events": [
"Adverse Events 1:",
" Total: 4/19 (21.05%)",
" Hemoglobin decreased 0/19 (0.00%)",
" Hemolysis 0/19 (0.00%)",
" Diarrhea 2/19 (10.53%)",
" Ear, nose and throat examination abnormal 0/19 (0.00%)",
" Esophageal ulcer 0/19 (0.00%)",
" Gastritis 1/19 (5.26%)",... | [
"INTERVENTION 1: ",
" Arm A",
" Patients receive oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. lapatinib ditosylate: Given PO and capecitabine: Given PO",
"INTERVE... | 5bc844fc-e852-4270-bfaf-36ea9eface3d | {
"candidate": "5bc844fc-e852-4270-bfaf-36ea9eface3d__substitute-syntactic_2",
"checks": {
"canonical": null,
"fidelity": "pass",
"guards": "pass",
"negation": null,
"relabel": null,
"retention": "pass",
"structural": "pass"
},
"effect": "preserving",
"fields": [
"Statement"
... |
5bc844fc-e852-4270-bfaf-36ea9eface3d__aug_recast_2 | Comparison | Intervention | NCT01928186 | NCT00684983 | While no primary trial participants receive oral capecitabine, oral lapatinib ditosylate, or cixutumumab IV, all secondary trial subjects receive these. | Contradiction | Base_Statement | null | null | {
"Adverse Events": [
"Adverse Events 1:",
" Total: 0/28 (0.00%)"
],
"Eligibility": [
"Inclusion Criteria:",
" A new diagnosis of invasive breast cancer > 1.0 cm in size, ER+ clinical stage I-III",
" Patient must have surgical resection followed by systemic adjuvant therapy with an aromatas... | [
"INTERVENTION 1: ",
" Diagnostic (FLT PET)",
" Patients with early stage, ER positive primary breast cancer undergo FLT PET scan at baseline and 1-6 weeks after the start of standard endocrine treatment. The surgery follows 1-7 days after the second FLT PET scan.",
" Tracer used in the FLT PET (positron em... | {
"Adverse Events": [
"Adverse Events 1:",
" Total: 4/19 (21.05%)",
" Hemoglobin decreased 0/19 (0.00%)",
" Hemolysis 0/19 (0.00%)",
" Diarrhea 2/19 (10.53%)",
" Ear, nose and throat examination abnormal 0/19 (0.00%)",
" Esophageal ulcer 0/19 (0.00%)",
" Gastritis 1/19 (5.26%)",... | [
"INTERVENTION 1: ",
" Arm A",
" Patients receive oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. lapatinib ditosylate: Given PO and capecitabine: Given PO",
"INTERVE... | 5bc844fc-e852-4270-bfaf-36ea9eface3d | {
"candidate": "5bc844fc-e852-4270-bfaf-36ea9eface3d__recast_2",
"checks": {
"canonical": null,
"fidelity": "pass",
"guards": "pass",
"negation": null,
"relabel": null,
"retention": "pass",
"structural": "pass"
},
"effect": "preserving",
"fields": [
"Statement"
],
"intent":... |
5bc844fc-e852-4270-bfaf-36ea9eface3d__aug_substitute-syntactic_3 | Comparison | Intervention | NCT01928186 | NCT00684983 | While all the secondary trial subjects' do, none of the primary trial participants receive cixutumumab IV, oral lapatinib ditosylate, or oral capecitabine. | Contradiction | Base_Statement | null | null | {
"Adverse Events": [
"Adverse Events 1:",
" Total: 0/28 (0.00%)"
],
"Eligibility": [
"Inclusion Criteria:",
" A new diagnosis of invasive breast cancer > 1.0 cm in size, ER+ clinical stage I-III",
" Patient must have surgical resection followed by systemic adjuvant therapy with an aromatas... | [
"INTERVENTION 1: ",
" Diagnostic (FLT PET)",
" Patients with early stage, ER positive primary breast cancer undergo FLT PET scan at baseline and 1-6 weeks after the start of standard endocrine treatment. The surgery follows 1-7 days after the second FLT PET scan.",
" Tracer used in the FLT PET (positron em... | {
"Adverse Events": [
"Adverse Events 1:",
" Total: 4/19 (21.05%)",
" Hemoglobin decreased 0/19 (0.00%)",
" Hemolysis 0/19 (0.00%)",
" Diarrhea 2/19 (10.53%)",
" Ear, nose and throat examination abnormal 0/19 (0.00%)",
" Esophageal ulcer 0/19 (0.00%)",
" Gastritis 1/19 (5.26%)",... | [
"INTERVENTION 1: ",
" Arm A",
" Patients receive oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. lapatinib ditosylate: Given PO and capecitabine: Given PO",
"INTERVE... | 5bc844fc-e852-4270-bfaf-36ea9eface3d | {
"candidate": "5bc844fc-e852-4270-bfaf-36ea9eface3d__substitute-syntactic_3",
"checks": {
"canonical": null,
"fidelity": "pass",
"guards": "pass",
"negation": null,
"relabel": null,
"retention": "pass",
"structural": "pass"
},
"effect": "preserving",
"fields": [
"Statement"
... |
5bc844fc-e852-4270-bfaf-36ea9eface3d__aug_substitute-syntactic_1 | Comparison | Intervention | NCT01928186 | NCT00684983 | While all secondary trial subjects receive oral capecitabine, oral lapatinib ditosylate, and cixutumumab IV, none of the primary trial participants receive them. | Contradiction | Base_Statement | null | null | {
"Adverse Events": [
"Adverse Events 1:",
" Total: 0/28 (0.00%)"
],
"Eligibility": [
"Inclusion Criteria:",
" A new diagnosis of invasive breast cancer > 1.0 cm in size, ER+ clinical stage I-III",
" Patient must have surgical resection followed by systemic adjuvant therapy with an aromatas... | [
"INTERVENTION 1: ",
" Diagnostic (FLT PET)",
" Patients with early stage, ER positive primary breast cancer undergo FLT PET scan at baseline and 1-6 weeks after the start of standard endocrine treatment. The surgery follows 1-7 days after the second FLT PET scan.",
" Tracer used in the FLT PET (positron em... | {
"Adverse Events": [
"Adverse Events 1:",
" Total: 4/19 (21.05%)",
" Hemoglobin decreased 0/19 (0.00%)",
" Hemolysis 0/19 (0.00%)",
" Diarrhea 2/19 (10.53%)",
" Ear, nose and throat examination abnormal 0/19 (0.00%)",
" Esophageal ulcer 0/19 (0.00%)",
" Gastritis 1/19 (5.26%)",... | [
"INTERVENTION 1: ",
" Arm A",
" Patients receive oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. lapatinib ditosylate: Given PO and capecitabine: Given PO",
"INTERVE... | 5bc844fc-e852-4270-bfaf-36ea9eface3d | {
"candidate": "5bc844fc-e852-4270-bfaf-36ea9eface3d__substitute-syntactic_1",
"checks": {
"canonical": null,
"fidelity": "pass",
"guards": "pass",
"negation": null,
"relabel": null,
"retention": "pass",
"structural": "pass"
},
"effect": "preserving",
"fields": [
"Statement"
... |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | Comparison | Adverse Events | NCT00093145 | NCT00703326 | Heart-related adverse events were recorded in both the primary trial and the secondary trial. | Entailment | Base_Statement | null | null | {
"Adverse Events": [
"Adverse Events 1:",
" Total: 5/32 (15.63%)",
" Febrile neutropenia 1/32 (3.13%)",
" Supraventricular tachycardia 1/32 (3.13%)",
" Hypersensitivity 2/32 (6.25%)",
" Catheter site infection 1/32 (3.13%)",
" Confusional state 1/32 (3.13%)"
],
"Eligibility": [
... | [
"Adverse Events 1:",
" Total: 5/32 (15.63%)",
" Febrile neutropenia 1/32 (3.13%)",
" Supraventricular tachycardia 1/32 (3.13%)",
" Hypersensitivity 2/32 (6.25%)",
" Catheter site infection 1/32 (3.13%)",
" Confusional state 1/32 (3.13%)"
] | {
"Adverse Events": [
"Adverse Events 1:",
" Total: 285/752 (37.90%)",
" Anaemia 2/752 (0.27%)",
" Disseminated intravascular coagulation 2/752 (0.27%)",
" Febrile neutropenia 51/752 (6.78%)",
" Neutropenia 47/752 (6.25%)",
" Thrombocytopenia 2/752 (0.27%)",
" Atrial fibrillatio... | [
"Adverse Events 1:",
" Total: 285/752 (37.90%)",
" Anaemia 2/752 (0.27%)",
" Disseminated intravascular coagulation 2/752 (0.27%)",
" Febrile neutropenia 51/752 (6.78%)",
" Neutropenia 47/752 (6.25%)",
" Thrombocytopenia 2/752 (0.27%)",
" Atrial fibrillation 1/752 (0.13%)",
" Atrial flutter ... | dbed5471-c2fc-45b5-b26f-430c9fa37a37 | {
"candidate": null,
"checks": null,
"effect": "original",
"fields": null,
"intent": null,
"mode": "original",
"strategies": null,
"summary": null,
"task_label_status": null,
"variant": 0
} |
dbed5471-c2fc-45b5-b26f-430c9fa37a37__aug_recast_3 | Comparison | Adverse Events | NCT00093145 | NCT00703326 | The primary trial recorded Heart-related adverse events. The secondary trial also recorded them. | Entailment | Base_Statement | null | null | {
"Adverse Events": [
"Adverse Events 1:",
" Total: 5/32 (15.63%)",
" Febrile neutropenia 1/32 (3.13%)",
" Supraventricular tachycardia 1/32 (3.13%)",
" Hypersensitivity 2/32 (6.25%)",
" Catheter site infection 1/32 (3.13%)",
" Confusional state 1/32 (3.13%)"
],
"Eligibility": [
... | [
"Adverse Events 1:",
" Total: 5/32 (15.63%)",
" Febrile neutropenia 1/32 (3.13%)",
" Supraventricular tachycardia 1/32 (3.13%)",
" Hypersensitivity 2/32 (6.25%)",
" Catheter site infection 1/32 (3.13%)",
" Confusional state 1/32 (3.13%)"
] | {
"Adverse Events": [
"Adverse Events 1:",
" Total: 285/752 (37.90%)",
" Anaemia 2/752 (0.27%)",
" Disseminated intravascular coagulation 2/752 (0.27%)",
" Febrile neutropenia 51/752 (6.78%)",
" Neutropenia 47/752 (6.25%)",
" Thrombocytopenia 2/752 (0.27%)",
" Atrial fibrillatio... | [
"Adverse Events 1:",
" Total: 285/752 (37.90%)",
" Anaemia 2/752 (0.27%)",
" Disseminated intravascular coagulation 2/752 (0.27%)",
" Febrile neutropenia 51/752 (6.78%)",
" Neutropenia 47/752 (6.25%)",
" Thrombocytopenia 2/752 (0.27%)",
" Atrial fibrillation 1/752 (0.13%)",
" Atrial flutter ... | dbed5471-c2fc-45b5-b26f-430c9fa37a37 | {
"candidate": "dbed5471-c2fc-45b5-b26f-430c9fa37a37__recast_3",
"checks": {
"canonical": null,
"fidelity": "pass",
"guards": "pass",
"negation": null,
"relabel": null,
"retention": "pass",
"structural": "pass"
},
"effect": "preserving",
"fields": [
"Statement"
],
"intent":... |
dbed5471-c2fc-45b5-b26f-430c9fa37a37__aug_negate_true-recast_1 | Comparison | Adverse Events | NCT00093145 | NCT00703326 | At least one of the primary trial or the secondary trial did not record Heart-related adverse events. | Contradiction | Base_Statement | null | null | {
"Adverse Events": [
"Adverse Events 1:",
" Total: 5/32 (15.63%)",
" Febrile neutropenia 1/32 (3.13%)",
" Supraventricular tachycardia 1/32 (3.13%)",
" Hypersensitivity 2/32 (6.25%)",
" Catheter site infection 1/32 (3.13%)",
" Confusional state 1/32 (3.13%)"
],
"Eligibility": [
... | [
"Adverse Events 1:",
" Total: 5/32 (15.63%)",
" Febrile neutropenia 1/32 (3.13%)",
" Supraventricular tachycardia 1/32 (3.13%)",
" Hypersensitivity 2/32 (6.25%)",
" Catheter site infection 1/32 (3.13%)",
" Confusional state 1/32 (3.13%)"
] | {
"Adverse Events": [
"Adverse Events 1:",
" Total: 285/752 (37.90%)",
" Anaemia 2/752 (0.27%)",
" Disseminated intravascular coagulation 2/752 (0.27%)",
" Febrile neutropenia 51/752 (6.78%)",
" Neutropenia 47/752 (6.25%)",
" Thrombocytopenia 2/752 (0.27%)",
" Atrial fibrillatio... | [
"Adverse Events 1:",
" Total: 285/752 (37.90%)",
" Anaemia 2/752 (0.27%)",
" Disseminated intravascular coagulation 2/752 (0.27%)",
" Febrile neutropenia 51/752 (6.78%)",
" Neutropenia 47/752 (6.25%)",
" Thrombocytopenia 2/752 (0.27%)",
" Atrial fibrillation 1/752 (0.13%)",
" Atrial flutter ... | dbed5471-c2fc-45b5-b26f-430c9fa37a37 | {
"candidate": "dbed5471-c2fc-45b5-b26f-430c9fa37a37__negate_true-recast_1",
"checks": {
"canonical": "not_applicable",
"fidelity": "pass",
"guards": "pass",
"negation": "pass",
"relabel": "not_applicable",
"retention": "pass",
"structural": "pass"
},
"effect": "label_negated",
"fi... |
dbed5471-c2fc-45b5-b26f-430c9fa37a37__aug_recast_1 | Comparison | Adverse Events | NCT00093145 | NCT00703326 | Both the primary trial and the secondary trial included records of Heart-related adverse events. | Entailment | Base_Statement | null | null | {
"Adverse Events": [
"Adverse Events 1:",
" Total: 5/32 (15.63%)",
" Febrile neutropenia 1/32 (3.13%)",
" Supraventricular tachycardia 1/32 (3.13%)",
" Hypersensitivity 2/32 (6.25%)",
" Catheter site infection 1/32 (3.13%)",
" Confusional state 1/32 (3.13%)"
],
"Eligibility": [
... | [
"Adverse Events 1:",
" Total: 5/32 (15.63%)",
" Febrile neutropenia 1/32 (3.13%)",
" Supraventricular tachycardia 1/32 (3.13%)",
" Hypersensitivity 2/32 (6.25%)",
" Catheter site infection 1/32 (3.13%)",
" Confusional state 1/32 (3.13%)"
] | {
"Adverse Events": [
"Adverse Events 1:",
" Total: 285/752 (37.90%)",
" Anaemia 2/752 (0.27%)",
" Disseminated intravascular coagulation 2/752 (0.27%)",
" Febrile neutropenia 51/752 (6.78%)",
" Neutropenia 47/752 (6.25%)",
" Thrombocytopenia 2/752 (0.27%)",
" Atrial fibrillatio... | [
"Adverse Events 1:",
" Total: 285/752 (37.90%)",
" Anaemia 2/752 (0.27%)",
" Disseminated intravascular coagulation 2/752 (0.27%)",
" Febrile neutropenia 51/752 (6.78%)",
" Neutropenia 47/752 (6.25%)",
" Thrombocytopenia 2/752 (0.27%)",
" Atrial fibrillation 1/752 (0.13%)",
" Atrial flutter ... | dbed5471-c2fc-45b5-b26f-430c9fa37a37 | {
"candidate": "dbed5471-c2fc-45b5-b26f-430c9fa37a37__recast_1",
"checks": {
"canonical": null,
"fidelity": "pass",
"guards": "pass",
"negation": null,
"relabel": null,
"retention": "pass",
"structural": "pass"
},
"effect": "preserving",
"fields": [
"Statement"
],
"intent":... |
dbed5471-c2fc-45b5-b26f-430c9fa37a37__aug_substitute-syntactic_1 | Comparison | Adverse Events | NCT00093145 | NCT00703326 | Both the primary trial and the secondary trial had documented Heart-related adverse events. | Entailment | Base_Statement | null | null | {
"Adverse Events": [
"Adverse Events 1:",
" Total: 5/32 (15.63%)",
" Febrile neutropenia 1/32 (3.13%)",
" Supraventricular tachycardia 1/32 (3.13%)",
" Hypersensitivity 2/32 (6.25%)",
" Catheter site infection 1/32 (3.13%)",
" Confusional state 1/32 (3.13%)"
],
"Eligibility": [
... | [
"Adverse Events 1:",
" Total: 5/32 (15.63%)",
" Febrile neutropenia 1/32 (3.13%)",
" Supraventricular tachycardia 1/32 (3.13%)",
" Hypersensitivity 2/32 (6.25%)",
" Catheter site infection 1/32 (3.13%)",
" Confusional state 1/32 (3.13%)"
] | {
"Adverse Events": [
"Adverse Events 1:",
" Total: 285/752 (37.90%)",
" Anaemia 2/752 (0.27%)",
" Disseminated intravascular coagulation 2/752 (0.27%)",
" Febrile neutropenia 51/752 (6.78%)",
" Neutropenia 47/752 (6.25%)",
" Thrombocytopenia 2/752 (0.27%)",
" Atrial fibrillatio... | [
"Adverse Events 1:",
" Total: 285/752 (37.90%)",
" Anaemia 2/752 (0.27%)",
" Disseminated intravascular coagulation 2/752 (0.27%)",
" Febrile neutropenia 51/752 (6.78%)",
" Neutropenia 47/752 (6.25%)",
" Thrombocytopenia 2/752 (0.27%)",
" Atrial fibrillation 1/752 (0.13%)",
" Atrial flutter ... | dbed5471-c2fc-45b5-b26f-430c9fa37a37 | {
"candidate": "dbed5471-c2fc-45b5-b26f-430c9fa37a37__substitute-syntactic_1",
"checks": {
"canonical": null,
"fidelity": "pass",
"guards": "pass",
"negation": null,
"relabel": null,
"retention": "pass",
"structural": "pass"
},
"effect": "preserving",
"fields": [
"Statement"
... |
20c35c89-8d23-4be3-b603-ac0ee0f3b4de | Single | Eligibility | NCT01097642 | null | Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial. | Contradiction | Base_Statement | null | null | {
"Adverse Events": [
"Adverse Events 1:",
" Total: 2/15 (13.33%)",
" Neutropenia 0/15 (0.00%)",
" GI Events 0/15 (0.00%)",
" Peripheral neuropathy 2/15 (13.33%)",
" Rash 0/15 (0.00%)",
"Adverse Events 2:",
" Total: 6/25 (24.00%)",
" Neutropenia 2/25 (8.00%)",
" GI... | [
"Inclusion Criteria:",
" Patients with histologic confirmation of invasive breast carcinoma.",
" Patients must have intact primary tumor.",
" Patients greater than or equal to 18 years.",
" Patients should have T1N1-3M0 or T2-4 N0-3M0.",
" Patients with bilateral breast cancer are eligible.",
" Pa... | null | null | 20c35c89-8d23-4be3-b603-ac0ee0f3b4de | {
"candidate": null,
"checks": null,
"effect": "original",
"fields": null,
"intent": null,
"mode": "original",
"strategies": null,
"summary": null,
"task_label_status": null,
"variant": 0
} |
20c35c89-8d23-4be3-b603-ac0ee0f3b4de__aug_biomedical-recast_1 | Single | Eligibility | NCT01097642 | null | The primary trial eligible patients are Adults with histologic confirmation of invasive Dukes A rectal cancer (T1 N1 M1). | Contradiction | Base_Statement | null | null | {
"Adverse Events": [
"Adverse Events 1:",
" Total: 2/15 (13.33%)",
" Neutropenia 0/15 (0.00%)",
" GI Events 0/15 (0.00%)",
" Peripheral neuropathy 2/15 (13.33%)",
" Rash 0/15 (0.00%)",
"Adverse Events 2:",
" Total: 6/25 (24.00%)",
" Neutropenia 2/25 (8.00%)",
" GI... | [
"Inclusion Criteria:",
" Patients with histologic confirmation of invasive breast carcinoma.",
" Patients must have intact primary tumor.",
" Patients greater than or equal to 18 years.",
" Patients should have T1N1-3M0 or T2-4 N0-3M0.",
" Patients with bilateral breast cancer are eligible.",
" Pa... | null | null | 20c35c89-8d23-4be3-b603-ac0ee0f3b4de | {
"candidate": "20c35c89-8d23-4be3-b603-ac0ee0f3b4de__biomedical-recast_1",
"checks": {
"canonical": "pass",
"fidelity": "pass",
"guards": "pass",
"negation": null,
"relabel": "pass",
"retention": "pass",
"structural": "pass"
},
"effect": "semantic_change",
"fields": [
"Stateme... |
End of preview. Expand in Data Studio
README.md exists but content is empty.
- Downloads last month
- -